SGLT2 inhibitors vs placebo
Death (all causes) · people with diabetes and CKD
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors leads to lower all‐cause death median compared with placebo (high certainty).
1 finding from 1 review · compare the 2 reviews
- Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes 2024 · Cochrane Headline outcomes onlyRR 0.86 [0.81, 0.92]20 studies · 44397 participantsHigh